60 Degrees Pharmaceuticals (SXTP) Net Income towards Common Stockholders (2022 - 2026)

60 Degrees Pharmaceuticals (SXTP) has reported Net Income towards Common Stockholders for 5 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 4.27% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$7.1 million (up 33.71% YoY), while the FY2025 annual figure was -$6.9 million, up 18.05% from the prior year.
• Net Income towards Common Stockholders retreated to -$2.1 million in Q1 2026 per SXTP's latest filing, from -$979497.0 in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $4.1 million in Q3 2023 and bottomed at -$4.3 million in Q2 2024.
• Historically, Net Income towards Common Stockholders has averaged -$1.7 million across 5 years, with a median of -$2.1 million in 2023.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 381.48% — and 2025, when it slumped 749.38%.
• 60 Degrees Pharmaceuticals' Net Income towards Common Stockholders stood at -$1.7 million in 2022, then dropped by 25.37% to -$2.1 million in 2023, then dropped by 4.93% to -$2.2 million in 2024, then jumped by 55.06% to -$979497.0 in 2025, then sank by 113.39% to -$2.1 million in 2026.
• Business Quant data shows SXTP's Net Income towards Common Stockholders at -$2.1 million in Q1 2026, -$979497.0 in Q4 2025, and -$2.3 million in Q3 2025.